NATROBA (spinosad) by Cipher Pharmaceuticals is insects. First approved in 2011.
Drug data last refreshed 13h ago · AI intelligence enriched 1w ago
NATROBA (spinosad) is a topical pediculicide suspension approved in 2011 for treatment of head lice and scabies infestations. The drug works by causing hyperexcitation in insects' nervous systems, leading to paralysis and death. Spinosad is a natural fermentation product with a unique mechanism distinct from pyrethrin-based competitors.
Product is mature with minimal Part D volume; small commercial footprint suggests limited sales team expansion and stable but niche market positioning.
insects. After periods of hyperexcitation, lice and mites become paralyzed and die.
Pediculicide
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
PK and Safety Study of Natroba Topical Suspension 0.9% in Subjects 1 Month to 3 Years 11 Months of Age With Scabies
Phase 3 Trial to Assess the Safety and Efficacy of Natroba for the Treatment of Scabies
Phase 3 Trial to Assess the Safety and Efficacy of Natroba for the Treatment of Scabies
Pharmacokinetic (PK) and Tolerance Study of Natroba Topical Suspension in Pediatrics With an Active Head Lice Infestation
A Dose Ranging Study of Different Strengths of Spinosad Topical Creme in Subjects With Pediculosis Capitis
Worked on NATROBA at Cipher Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moNATROBA offers limited career growth due to minimal linked job openings (0) and a niche, stable market with low competitive intensity. Career professionals on this product should expect focused commercial execution rather than expansion opportunities, with emphasis on dermatology and specialty pharmacy relationships.